MARKET

CDMO

CDMO

Avid Bioservices
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.62
+0.73
+4.08%
Opening 12:43 02/24 EST
OPEN
17.86
PREV CLOSE
17.89
HIGH
18.67
LOW
17.59
VOLUME
286.87K
TURNOVER
--
52 WEEK HIGH
19.35
52 WEEK LOW
3.020
MARKET CAP
1.13B
P/E (TTM)
-211.8316
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Do Institutions Own Avid Bioservices, Inc. (NASDAQ:CDMO) Shares?
A look at the shareholders of Avid Bioservices, Inc. ( NASDAQ:CDMO ) can tell us which group is most powerful. Insiders...
Simply Wall St. · 12h ago
Pacira Pharmaceuticals Getting Closer To Key Technical Measure
Investor's Business Daily · 21h ago
Avid Bioservices gives update on Myford manufacturing capacity expansion plan
Biologics contract development and manufacturing company Avid Bioservices (CDMO) announced the initiation of Phase 2 of the company’s two-phase effort to expand the overall manufacturing capacity within its Myford facility.The company
Seekingalpha · 2d ago
Avid Bioservices Highlights Beginning Of Phase 2 Of Its Myford Manufacturing Capacity Expansion Plan
Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processing Suites Phase 2 Has Potential to Increase Annual Revenue Generating Capacity
Benzinga · 2d ago
Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan
Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processing Suites Phase 2 Has Potential to Increase Annual Revenue Generating Capacity by an Additional $100 Million TUSTIN, ...
GlobeNewswire · 2d ago
Avid Bioservices Begins Phase 2 of Myford Facility Expansion; Shares Rise Midday
MT Newswires · 2d ago
Inovio Pharmaceuticals Shows Market Leadership With Jump To 86 RS Rating
Investor's Business Daily · 5d ago
Humanigen and Avid Bio ink manufacturing deal for lenzilumab in COVID-19
Avid Bioservices (CDMO), up 7% premarket and Humanigen (HGEN) have entered into a manufacturing services agreement to expand production capacity for lenzilumab, latter's therapeutic candidate in development for COVID-19.Under the terms of this
Seekingalpha · 02/03 12:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDMO. Analyze the recent business situations of Avid Bioservices through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDMO stock price target is 17.67 with a high estimate of 22.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 201
Institutional Holdings: 42.72M
% Owned: 70.55%
Shares Outstanding: 60.56M
TypeInstitutionsShares
Increased
50
5.01M
New
53
4.87M
Decreased
29
4.62M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.34%
Pharmaceuticals & Medical Research
+1.43%
Key Executives
Non-Executive Chairman/Independent Director
Joseph Carleone
President/Chief Executive Officer/Director
Nicholas Green
Chief Financial Officer
Daniel Hart
Chief Operating Officer
Richard Richieri
Vice President/General Counsel/Secretary
Mark Ziebell
Vice President
Magnus Schroeder
Other
Timothy Compton
Director
Richard Hancock
Other
Tim Compton
Independent Director
Mark Bamforth
Independent Director
Catherine Mackey
Independent Director
Gregory Sargen
Independent Director
Jeanne Thoma
Independent Director
Patrick Walsh
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
03/07/2018
Dividend USD 0.6563
03/16/2018
About CDMO
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company is focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biopharmaceutical products derived from mammalian cell culture. The Company provides a range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The Company’s services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.

Webull offers kinds of Avid Bioservices Inc stock information, including NASDAQ:CDMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDMO stock methods without spending real money on the virtual paper trading platform.